Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : Raises Precigen Stake to 14.8% With Note Conversion

10/09/2020 | 08:06am EST

By Colin Kellaher

Precigen Inc. on Friday said Germany's Merck KGaA elected to convert a $25 million note into common stock, raising its stake in the biopharmaceutical company to 14.8% from 11.6%.

The Germantown, Md., company issued the note to Merck in late 2018 as part of a deal in which Merck reassigned to Precigen its exclusive chimeric antigen receptor T-cell development rights.

Germany's Merck, which remains Precigen's second-largest shareholder, also received $150 million in stock as part of the transaction.

Precigen said the note would have otherwise converted in December.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-09-20 0805ET

Stocks mentioned in the article
ChangeLast1st jan.
MERCK KGAA 0.62% 130.7 Delayed Quote.23.30%
PRECIGEN, INC. 2.36% 6.08 Delayed Quote.8.39%
All news about MERCK KGAA
08:36aDeutsche Bank's Depositary Receipts Virtual Investor Conference presentations..
AQ
04:37aMERCK KGAA : Correction of a release from 25/03/2020 according to Article 40, Se..
EQ
11/23MERCK : Massachusetts-based Businesses of Merck KGaA, Darmstadt, Germany named t..
AQ
11/23MERCK KGAA : Release according to Article 40, Section 1 of the WpHG [the German ..
EQ
11/19MERCK : EMD Serono's Embracing Carers Announces Study Results on COVID-19 and Ca..
AQ
11/17MERCK KGAA : UBS reiterates its Neutral rating
MD
11/16MERCK KGAA : Goldman Sachs keeps a Sell rating
MD
11/16MERCK KGAA : JP Morgan remains Neutral
MD
11/13MERCK KGAA : Deutsche Bank keeps its Buy rating
MD
11/13MERCK KGAA : Credit Suisse maintains a Buy rating
MD
More news
Financials
Sales 2020 17 381 M 20 673 M 20 673 M
Net income 2020 2 013 M 2 394 M 2 394 M
Net Debt 2020 11 224 M 13 350 M 13 350 M
P/E ratio 2020 28,0x
Yield 2020 1,08%
Capitalization 56 825 M 67 521 M 67 589 M
EV / Sales 2020 3,92x
EV / Sales 2021 3,63x
Nbr of Employees 58 077
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 135,37 €
Last Close Price 130,70 €
Spread / Highest target 29,3%
Spread / Average Target 3,57%
Spread / Lowest Target -22,7%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA23.30%66 719
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD96.71%20 035
KYOWA KIRIN CO., LTD.9.60%14 124
BETTA PHARMACEUTICALS CO., LTD.48.37%6 114
YUHAN CORPORATION39.11%3 709
RECIPHARM AB (PUBL)16.10%1 776